[A22-51] Abemaciclib (breast cancer) – Benefit assessment according to §35a Social Code Book V

Last updated 20.10.2022

Project no.:

Commission awarded on 29.04.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adjuvant treatment of patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

Result of dossier assessment:
  • Premenopausal women: hint of minor added benefit
  • Postmenopausal women: added benefit not proven
  • Men: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-10-10.

Federal Joint Committee (G-BA)

2022-10-20 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form